Please login to the form below

Not currently logged in
Email:
Password:

Efient

This page shows the latest Efient news and features for those working in and with pharma, biotech and healthcare.

Lilly’s Efient and Sucampo's Amitiza win NICE backing

Lilly’s Efient and Sucampo's Amitiza win NICE backing

Lilly’ s Efient and Sucampo's Amitiza win NICE backing. Blood clot and constipation drugs recommended for NHS use. ... New Efient guidance. NICE also updated the guidance for blood clot prevention drug Efient to include a wider reach of patients.

Latest news

  • Merz, Lilly and Daiichi-Sankyo breach ABPI code Merz, Lilly and Daiichi-Sankyo breach ABPI code

    The case involving Lilly and Daiichi-Sankyo was to do with the companies' promotional activities concerning the heart drug Efient (known as Effient outside the EU). ... the off-label use of Efient beyond its maximum licensed duration of treatment, and as

  • Coronary conundrums

    Eli Lilly's prasugrel (Effient, Efient and Prasita) is an antiplatelet that represents an advance over clopidogrel, with more potent and consistent inhibition of the same P2Y12 receptor.

  • Straight from the heart

    Efient (Daiichi Sankyo/Lilly). 16%. 3. Pradaxa (Boehringer Ingelheim). 13%. 4=. Angiox (Nycomed). ... Efient, another recent launch, may be the most likely to have used an educational meeting strategy.

  • Close but no cigar

    Actinic keratosis. Argentina, Mexico. Prasugrel. Efient (Daiichi Sankyo, Eli Lilly). Acute coronary syndromes.

  • Antiplatelet heart drug launched

    Antiplatelet heart drug launched. UK patients are the first to benefit from new heart drug, prasugrel (Efient), following authorisation by the European Medicines Agency. ... UK patients are the first to benefit from new heart drug, prasugrel (Efient),

More from news
Approximately 2 fully matching, plus 4 partially matching documents found.

Latest appointments

  • Milestone names chief medical officer Milestone names chief medical officer

    His other big pharma experience includes roles at Daiichi-Sankyo, Novartis, and Bristol Myers Squibb, working on cardiovascular products including Efient, Diovan and Approvel.

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Grace Communications

Grace Communications is a creative agency specialising in healthcare communication and understanding people's personality types....

Latest intelligence

Island
Pharma’s isolated islands of innovation
With service design and technology often failing the patient, why perspective on improving outcomes need to change...
Uncertainty, austerity and Brexit
What does it mean for the life science sector?...
The Holy Grail of HCP Access
This is the data you need to gain access....

Infographics